×
About 1,075 results

ALLMedicine™ Adult T-cell Leukemia/lymphoma Center

Research & Reviews  381 results

Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia/lymphoma.
https://doi.org/10.1007/s12185-023-03547-5
International Journal of Hematology; Yasunaga JI

Jan 28th, 2023 - Adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature CD4 + T cells induced by human T-cell leukemia virus type I (HTLV-1). HTLV-1 maintains life-long infection in the human host by clonal proliferation of infected cells and cell-to-cell ...

Tissue Collection for Studies of Lymph Cancer
https://clinicaltrials.gov/ct2/show/NCT01676805

Jan 25th, 2023 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

SBNO2 is a critical mediator of STAT3-driven hematological malignancies.
https://doi.org/10.1182/blood.2022018494
Blood Brandstoetter T, Schmoellerl J et. al.

Jan 12th, 2023 - Gain-of-function mutations in the STAT3 gene are recurrently identified in patients suffering from large granular lymphocytic leukemia (LGLL) and some cases of T/NK and adult T-cell leukemia/lymphoma. To understand the consequences and molecular m...

Advances in the treatment of HTLV-1-associated adult T-cell leukemia lymphoma.
https://doi.org/10.1016/j.coviro.2022.101289
Current Opinion in Virology; Phillips AA

Dec 31st, 2022 - Adult T-cell leukemia/lymphoma (ATLL) is an aggressive hematologic malignancy linked to HTLV-1 infection, which is refractory to therapy. The precise mechanism of oncogenesis in ATLL is incompletely understood, however, oncogenic viral genes Tax a...

Isolated cardiac valve involvement in smoldering adult T-cell leukemia/lymphoma.
https://doi.org/10.1016/j.carpath.2022.107513
Cardiovascular Pathology : the Official Journal of the So... Aguilar C, Beltran BE et. al.

Dec 26th, 2022 - Adult T-cell leukemia/lymphoma (ATLL) is an aggressive mature T-cell neoplasm caused by infection with the Human T-cell Lymphotropic Virus Type 1 (HTLV-1). Cardiac involvement in patients with ATLL is infrequent, and when it happens it is usually ...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  17 results

Tissue Collection for Studies of Lymph Cancer
https://clinicaltrials.gov/ct2/show/NCT01676805

Jan 25th, 2023 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03264131

Dec 1st, 2022 - STUDY OBJECTIVES Primary Objective To define the proportion of subjects with CR after 4-6 cycles of brentuximab vedotin in combination with cyclophosphamide, doxorubicin, etoposide, and prednisone (BV-CHEP) in the treatment of adult T-cell leukemi...

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04848064

Nov 21st, 2022 - PRIMARY OBJECTIVE: I. To determine safety, tolerability, and determine the maximum tolerated dose (MTD) of IL-21 expanded, off the shelf, third-party natural killer (NK) cells and mogamulizumab in patients with relapsed/refractory cutaneous T-cell...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Nov 4th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT03905135

Sep 13th, 2022 - Background: Mature T-cell cancers are a phenotypically heterogeneous group of malignancies which constitute 10-15% of all non-Hodgkin lymphomas (NHL). Patients with relapsed/refractory T cell lymphomas have limited therapeutic options, making new ...

see more →

News  31 results

Japan Green Lights Valemetostat Tosilate for Relapsed/Refractory Adult T-cell Leukemia/Lymphoma
https://www.onclive.com/view/japan-green-lights-valemetostat-tosilate-for-relapsed-refractory-adult-t-cell-leukemia-lymphoma

Sep 26th, 2022 - The Japan Ministry of Health, Labor and Welfare (MHLW) has approved valemetostat tosilate (Ezharmia; DS-3201b) for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL).1 The regulatory decision was based on r...

Dr. Zain on Investigational Approaches in Peripheral T-Cell Lymphoma
https://www.onclive.com/view/dr-zain-on-investigational-approaches-in-peripheral-tcell-lymphoma

Oct 6th, 2021 - Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses investigational approaches in peripheral T-cell lymphoma....

Remaining ECHELON-2 Questions Spark Novel Research Efforts in PTCL
https://www.onclive.com/view/remaining-echelon-2-questions-spark-novel-research-efforts-in-ptcl

Feb 17th, 2021 - Questions from the phase 3 ECHELON-2 trial (NCT01777152), which led to the 2018 FDA approval of brentuximab vedotin (Adcetris) plus chemotherapy for patients with CD30-expressing peripheral T-cell lymphoma (PTCL), have given way to additional rese...

An International Experience at Home
https://www.onclive.com/view/an-international-experience-at-home

Dec 5th, 2020 - Christopher Dittus, DO, MPH I often find myself in awe of physicians who travel around the world seeking out the 2 most desirable aspects of medicine—patients in desperate need of medical care and patients with genuinely novel pathology. The dow...

Interferon Therapy: A Growing Family Feeds New Interest in an Older Treatment
https://www.onclive.com/view/interferon-therapy-a-growing-family-feeds-new-interest-in-an-older-treatment

Dec 5th, 2020 - More than half a century has passed since interferons (IFNs) were first discovered. Since then, they have evolved from a cure-all for cancer, as they were initially touted, to a more tempered yet equally vital role in treating a number of differen...

see more →